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Objectives This study examined whether sirolimus-eluting stent (SES) implantation may affect endothelial vasomotor dys-
function in resistance and epicardial infarct-related coronary arteries in acute myocardial infarction (AMI).
Background Myocardial ischemia-reperfusion causes endothelial injury entirely in the vasculature of the infarct-related coro-
nary artery. Sirolimus-eluting stent implantation inhibits re-endothelialization at the site of stenting.
Methods This study included 29 patients with a first AMI due to occlusion of the left anterior descending coronary artery
(LAD) and successful reperfusion therapy using a SES (n  13) or bare-metal stent (BMS) (n  16). The diame-
ter of the epicardial segment distal to the site of SES deployment and coronary blood flow in the LAD in re-
sponse to an intracoronary infusion of acetylcholine were measured at 2 weeks after AMI. Levels of vascular
endothelial growth factor (VEGF) were measured by enzyme-linked immunoadsorbent assay in plasma obtained
from the aortic root (AO) and the anterior interventricular vein (AIV) in all patients.
Results The epicardial coronary artery was more severely constricted in response to acetylcholine in the SES than
in the BMS group. The increase in coronary blood flow in response to acetylcholine was lower in the SES than in
the BMS group. Vascular endothelial growth factor levels in the AIV were significantly lower than in the AO in the
SES group but not in the BMS group.
Conclusions During the course of AMI, SES implantation adversely affects endothelium-dependent vasomotor function in re-
sistance and epicardial coronary arteries after the ischemia-reperfusion in association with a reduction in myo-
cardial VEGF secretion. (J Am Coll Cardiol 2007;50:1305–9) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.031s
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dyocardial ischemia-reperfusion induces endothelial injury
n the entire vascular trees of the infarct-related coronary
rtery (1). Endothelial damage that occurrs during reperfu-
ion injury may limit the restoration of blood flow to
otentially viable ischemic myocardium, which importantly
ontributes to infarct extension and poor prognosis after
cute myocardial infarction (AMI) (2). Vascular endothelial
rowth factor (VEGF) is produced and expressed in the
yocardium and the coronary vascular bed, and its expres-
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refecture, Japan. This study was supported by Grants-in-Aid for (B)(2)-15390244
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ccepted June 19, 2007.ion is elevated in patients with AMI (3). The up-regulation
f VEGF may be a compensatory mechanism for the
eversal of reperfusion-induced coronary microvascular in-
ury via endothelial repair and microvessel growth in the
nfarcted myocardium (3–5).
Drug-eluting stents (DES) in percutaneous coronary
ntervention remarkably reduce restenosis and revascular-
zation rate in comparison with a bare-metal stent (BMS)
6). However, endothelial dysfunction at the peri-DES
oronary segments can cause spasm in the stented coro-
ary arteries after implantation of DES (7,8). It has been
hown that sirolimus is capable of reducing expression of
EGF in vascular cells and VEGF-induced endothelial
roliferation (9). Thus, we examined our hypothesis that
iffusion of sirolimus into coronary blood flowing
hrough a stent may directly or indirectly impair the recovery
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DES and Endothelial Dysfunction October 2, 2007:1305–9of reperfusion-induced endothelial
injury entirely in the infarct-
related coronary artery beyond the
distal edge of the SES early after
AMI.
Methods
Study patients and control sub-
jects. This study included 29
consecutive patients with a first
AMI due to occlusion of a
proximal segment of the left
anterior descending coronary
artery (LAD), who were admit-
ted within 12 h after symptom
onset to Yamanashi University
Hospital between January 2004
and July 2006. Diagnosis of
AMI was based on the presence
of all of the following criteria:
ypical chest pain persisting for 30 min, ST-segment
levation of 0.2 mV in 2 contiguous leads on the
tandard 12-lead electrocardiogram, and elevation of
erum creatine kinase levels to more than twice the upper
imit of normal. All of the study patients received
mergent coronary angiography and successful reperfu-
ion therapy by primary percutaneous coronary interven-
ion using sirolimus-eluting stents (SES) (n  13) or
MS (n  16) after ballooning coronary angioplasty.
ecause SES did not become available in Japan until
ugust 2004, all patients treated before this date received
MS. Because clopidogrel was not available until May
006 in Japan, SES was used only in patients who were
onfirmed to have no side effects from the previous use of
iclopidine, and BMS was used in the remaining patients.
he exclusion criteria were as follows: 1) residual organic
tenosis 30% in the LAD; 2) previous percutaneous
oronary intervention in the LAD; 3) percutaneous
oronary intervention at multiple segments of the LAD;
) previous coronary artery bypass surgery; 5) congestive
eart failure at 1 week after AMI; 6) persistent atrial
brillation or a paced rhythm; 7) presence of collaterals to
he LAD with Rentrop grade 2 at the emergent
oronary angiography; 8) coronary artery spasm in the
AD (40% decrease in coronary epicardial diameter
rom baseline) in response to the intracoronary infusion
f acetylcholine (ACh) (10); and 9) valvular heart dis-
ases, secondary hypertension, stroke, renal dysfunction
serum creatinine concentration 2.0 mg/dl), or other
erious diseases. This study also included 12 control
ubjects who were selected from 57 consecutive subjects
ith normal coronary angiograms and left ventriculo-
rams to match the age, gender, and other traditional risk
actors of the AMI patients. These control subjects
Abbreviations
and Acronyms
ACh  acetylcholine
AIV  anterior
interventricular vein
AMI  acute myocardial
infarction
AO  aortic root
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
LAD  left anterior
descending coronary artery
LCx  left circumflex
artery
SES  sirolimus-eluting
stent(s)
VEGF  vascular
endothelial growth factorerved as a reference group for the coronary vasomotor wesponse and the plasma VEGF concentrations. The
linical characteristics of the patients with AMI and the
ontrol subjects are shown in Table 1. Written informed
onsent was obtained from all patients and control
ubjects before the study. The study was in agreement
ith the guidelines approved by the ethics committee at
amanashi University Hospital.
tudy protocol and assays. Coronary angiography was
erformed twice in all AMI patients, immediately after
dmission during the acute phase of AMI and at 2 weeks
fter AMI. The measurements of coronary vasomotor re-
ponse and left ventriculography were performed at the
econd coronary angiography after an overnight fast in all of
he AMI patients. Blood sampling from the anterior inter-
entricular vein (AIV) and the aortic root (AO) was
erformed before systemic heparinization on the third day
fter AMI in 8 patients with SES implantation and at the
ime of the second coronary angiography in all of the AMI
atients, as described in our previous report (10). Also, the
easurement of coronary vasomotor response and the blood
ampling were performed only once in all of the control
ubjects. Plasma levels of free VEGF were measured by
sandwich enzyme-linked immunoadsorbent assay (R&D
ystems, Minneapolis, Minnesota). Sirolimus levels in
omparisons of Coronary Risk Factors, Cardiacedications, Baseline Coronary Diameter, andlood Flow Among AMI Patients Treated With BMSr SES and C ntrol Subjects
Table 1
Comparisons of Coronary Risk Factors, Cardiac
Medications, Baseline Coronary Diameter, and
Blood Flow Among AMI Patients Treated With BMS
or SES and Control Subjects
AMI (n  29) Control
Subjects
(n  12)SES (n  13) BMS (n  16)
Age (yrs) 63.6 10.1 65.1 12.4 64.1 6.2
Men (%) 69.2 75.0 75.0
BMI (kg/m2) 24.6 2.0 24.9 3.3 24.4 2.6
Hypertension (%) 69.2 68.8 41.7
Hyperlipidemia (%) 69.2 68.8 50.0
Diabetes mellitus (%) 38.5 50.0 25.0
Smoking (%) 46.2 56.3 33.3
No. of diseased vessels 1.6 0.8 1.7 0.7 —
Medication (%)
Aspirin 100 100 0
Ticlopidine 100 100 0
ACEI or ARB 84.6 87.5 58.3
Statin 69.2 68.8 41.7
Calcium-channel blocker 61.5 62.5 83.3
Beta-blocker 30.8 31.3 25.0
Nitrates 7.7 12.5 0
Diuretics 30.8 31.3 16.7
Ejection fraction (%) 46.9 6.9 45.5 6.7 71.4 6.8
Baseline LAD diameter (mm) 2.6 0.3 2.7 0.6 2.7 0.5
Baseline LCx diameter (mm) 2.8 0.2 2.9 0.3 2.9 0.3
Baseline CBF (ml/min) 36.2 15.0 35.5 6.3 38.4 18.2
ata are expressed as mean  SD or percentage.
ACEI  angiotensin-converting enzyme inhibitor; AMI  acute myocardial infarction; ARB 
ngiotensin receptor blocker; BMI  body mass index; BMS  bare-metal stent; CBF  coronary
lood flow; LAD  left anterior descending artery; LCx  left circumflex artery; SES  sirolimus-
luting stent.hole blood were determined by high-performance liquid
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October 2, 2007:1305–9 DES and Endothelial Dysfunctionhromatography/mass spectroscopy (11). The minimum
etection limit for sirolimus was 0.1 ng/ml. All lipid-
owering drugs and vasodilators were withdrawn more than
days before the coronary angiographic study in patients
ith AMI and control subjects.
rotocol for measurements of coronary vasomotor
esponses. After the blood sampling, a quantitative coro-
ary angiographic study was performed in all of the AMI
atients and the control subjects as in our previous report
10). After baseline angiography, incremental doses of ACh
5, 10, and 50 g/min) were infused directly into the left
oronary artery through the Judkins catheter. After an
dditional 15 min, intracoronary sodium nitroprusside
10 g/min) was infused in the same manner as ACh. After
nother 15 min, intracoronary isosorbide dinitrate (1 mg)
as administered. Coronary angiography was repeated be-
ore and during each infusion.
uantitative coronary angiography and coronary blood
ow measurement. Luminal diameter at the segment be-
ween 15 and 25 mm distal to the stent edge in the LAD
nd at the proximal segment with no previous percutaneous
oronary intervention in left circumflex artery (LCx) as a
eference was measured quantitatively (Cardio 500, Kontron
nstruments, Munich, Germany) (10). Luminal diameter at
he midsegment of the LAD was measured in all of the
ontrol subjects in the same manner as in the AMI patients.
Blood flow velocity was measured using a 0.014-inch wire
quipped with a Doppler crystal at its tip (FloWire, Car-
iometrics, Mountain View, California). The wire was
arefully positioned in a segment of the LAD 5 to 15 mm
rom distal edge of the stent (10). Coronary blood flow
ml/min) was estimated from coronary blood flow velocity
Flow Map, Cardiometrics), as described previously (10).
Responses of the coronary artery diameter and coronary
lood flow to infusions of ACh, nitrates, and sodium
itroprusside were expressed as percent changes from base-
ine values taken just before each infusion.
tatistical analysis. Data are expressed as the mean 
tandard deviation or percentage. The frequencies between
groups of patients and the 2 mean values were compared
sing chi-square test and Student paired or unpaired t test,
espectively. When more than 2 groups were compared, a
-way analysis of variance was performed followed by a
heffe test for post-hoc comparison of group means. The
ean values of coronary vasomotor responses between the 2
atient groups were compared using 2-way analysis of
ariance for repeated measures followed by post-hoc testing
ith a Sheffe test. When frequencies among the patients
ith SES, those with BMS, and control subjects were
ompared, chi-square test using a 2  3 contingency table
as initially examined for independence of frequencies
mong the 3 groups. When significant in independence by
hi-square test, wholly significant difference was calculated
Tukey test) between the 2 groups. A confidence level of
 0.05 was considered statistically significant. Analyses pere performed in part with StatView 5.0 (SAS Institute,
ary, North Carolina).
esults
omparisons of coronary risk factors, cardiac medica-
ions, lesion and procedural variables of coronary inter-
ention, and AMI-related variables among patients
roups and control subjects. There were no statistically
ignificant differences in the coronary risk factors among the
MI patients treated with SES or BMS, and the control
ubjects, as shown in Table 1. There was no significant
ifference in cardiac medications and variables related to
MI and coronary intervention between the SES and the
MS groups (Tables 1 and 2). Intravascular ultrasound
tudy at the end of the second coronary angiographic study
howed no dissections on the LAD in both the SES and the
MS groups (data not shown).
esponse of epicardial coronary vasomotor and coronary
lood flow. At baseline, the epicardial diameters of the
AD and LCx and coronary blood flow of the LAD were
imilar among the AMI patients treated with SES, those
ith BMS, and the control subjects (Table 1). Infusion of
Ch into the LAD, the infarct-related coronary artery,
esulted in less epicardial dilation and increase in blood flow
n patients treated with SES or BMS as compared with
ontrol subjects (Figs. 1A and 1C). Moreover, the LAD in
atients treated with SES had a greater impairment of
picardial dilation and less of a blood flow increase in
esponse to ACh as compared with that in patients treated
ith BMS (Figs. 1A and 1C). The epicardial dilation and
omparisons of AMI-Related Variablesnd Les on and Procedural Variables During PCI
Table 2 Comparisons of AMI-Related Variablesand Lesion and Procedural Variables During PCI
SES (n  13) BMS (n  16)
Profile regarding AMI
Peak CK (mg/dl) 3,152 2,128 3,220 2,282
Time to reperfusion (h) 4.5 2.6 4.7 3.4
MBG score (%)
0 0 0
1 0 0
2 46.2 43.7
3 53.8 56.3
Forrester subset (%)
1 53.8 50.0
2 23.1 31.3
3 23.1 18.7
4 0 0
PCI-related variables
Lesion length (mm) 13.4 4.3 13.1 4.9
Stent diameter (mm) 3.0 0.4 3.1 0.3
Stent length (mm) 20.7 4.4 17.8 5.3
Deployment pressure (atm) 15.4 2.7 13.9 2.3
Postdilatation (%) 53.8 31.3
MLD after stenting (mm) 2.7 0.3 2.8 0.3
ata are expressed as mean  SD or percentage.
CK creatine kinase; MBGmyocardial blush grade; MLDminimal luminal diameter; PCI
ercutaneous coronary intervention; other abbreviations as in Table 1.
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DES and Endothelial Dysfunction October 2, 2007:1305–9he increase in blood flow of LAD in response to
ndothelium-independent vasodilators, isosorbide dinitrate
r sodium nitroprusside, were comparable among the SES-
nd BMS-treated patients, and the control subjects (Fig. 2).
oreover, the epicardial coronary vasomotor responses to
Ch and nitrates of the LCx, as a reference artery, were
imilar between the SES- and BMS-treated patients with
MI (Figs. 1B and 2A).
EGF levels. The AO levels of VEGF were significantly
igher in the AMI patients treated with either SES or BMS
han in control subjects, as shown in Figure 3. The AO
evels of VEGF were similar between the AMI patients
reated with SES and BMS. However, the AIV levels of
EGF were significantly lower than the AO levels in the
ES patients, whereas the AIV levels of VEGF were similar
Figure 1 Comparisons of Coronary Vasomotor Responses
to ACh in AMI Patients and Control Subjects
Comparisons of vasomotor responses to acetylcholine (ACh) in acute myocar-
dial infarction (AMI) patients treated with a sirolimus-eluting stent (SES) (n 
13) or bare-metal stent (BMS) (n  16) and control subjects (n  12). (A) Per-
cent change in epicardial diameter of the left anterior descending coronary
artery (LAD) from baseline in response to ACh. (B) Percent change in epicardial
diameter of the left circumflex artery (LCx), a reference artery, from baseline in
response to ACh. (C) Percent change in coronary blood flow (CBF) of the LAD
from baseline in response to ACh.o the AO levels in the BMS patients (Fig. 3).lasma sirolimus concentrations. The AIV levels of
irolimus were significantly higher than the AO levels after
ES implantation on the third day and at 2 weeks after
MI (the third day after AMI: 0.47  0.03 ng/ml vs.
.37  0.02 ng/ml, respectively, n  8, p  0.03; 2 weeks
fter AMI: 0.19  0.01 ng/ml vs. 0.17  0.01 ng/ml,
espectively, n  13, p  0.03).
iscussion
he present study demonstrated that SES implantation
ggravated endothelium-dependent vasomotor dysfunction
n both large vessels and the microvasculature of the
nfarct-related coronary artery after reperfusion therapy
uring the early course of AMI. The present study revealed
hat low but significant levels of sirolimus (0.14  0.68
g/ml [0.15 0.74 nmol/l]) were detected in both AIV and
O and that sirolimus was released from SES into coronary
lood until at least 2 weeks after the SES implantation.
hese concentrations were 10  1,000-fold lower than the
evels that inhibited endothelium-dependent relaxation in
he animal experiments (12,13). However, it cannot be
Figure 2 Comparisons of Coronary Vasomotor Responses to
ISDNs or SNP in AMI Patients and Control Subjects
Comparisons of vasomotor responses to isosorbide dinitrates (ISDNs) or
sodium nitroprusside (SNP) in AMI patients treated with an SES (n  13) or
BMS (n  16) and control subjects (n  12). (A) Percent change in epicardial
diameter of the LAD and the LCx from baseline in response to ISDN. (B) Per-
cent change in CBF of the LAD from baseline in response to SNP. Abbrevia-
tions as in Figure 1.
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October 2, 2007:1305–9 DES and Endothelial Dysfunctionxcluded that chronic exposure to sirolimus in the coronary
irculation for 2 weeks might cause a considerable accumula-
ion of this drug in the vascular bed distal to the site of SES
mplantation, leading to selective aggravation of endothelial
asomotor dysfunction in the infarct-related coronary artery.
Furthermore, the present study demonstrated that there
as a step down in VEGF levels from the AO to AIV in
atients with SES implantation but not in those with BMS
mplantation. These findings suggest that SES implantation
ay decrease the release of VEGF from the myocardial
egion supplied by the LAD, which may play a possible role
n endothelial vasomotor dysfunction in infarct-related cor-
nary arteries treated with SES.
A limitation of the present study was that the stent type
as not randomized, and a small number of patients were
nrolled. The data are preliminary, and large randomized
tudies are required to confirm the present data.
onclusions
irolimus-eluting stent implantation aggravates endothelium-
Figure 3 VEGF Levels in the Plasma From the AIV
and the AO in AMI Patients and in Control Subjects
Vascular endothelial growth factor (VEGF) levels (pg/ml) in the plasma from the
anterior interventricular vein (AIV) and the aortic root (AO) at 2 weeks after AMI
in AMI patients treated with an SES (n  13) or BMS (n  16) and in control
subjects (n  12). Abbreviations as in Figure 1.ependent vasomotor dysfunction in resistance and large ves-els of the infarct-related coronary arteries in association with a
eduction in myocardial VEGF secretion during the early
ourse of AMI.
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